For our Members, please find below the list of our latest Model Portfolio changes.
Biogen Inc. – Common is a current holding in our US high conviction portfolio.
The stock price rallied following the FDA decision, which was announced earlier this week, to approve Biogen’s drug Aducanumab, a treatment for Alzheimer’s disease.
ETFS S&P Biotech has been an overweight portfolio allocation and either taking profit now or sticking with the position, whilst the price action remains above the 10-day average, will provide a positive outcome.
The added buying interest in the US biotech sector following the recent announcement from Biogen is helping propel the CURE ETF.
Buy TPG Telecom above the $5.06 higher low formation.
Traders should consider applying a stop loss below the recent pivot low of $4.81 or on a break of $5.06.
TPG offers solid free cash flow with an improving dividend story into FY22 and FY23.
12/6 Update: We continue to hold TPG and suggest traders stick with the trade as long as the price action remains above the 10 day average. The stock is now up over 10% since our entry condition was met earlier this month.
WPL:ASX is under Algo Engine buy conditions and is a current holding in our ASX model portfolio.
12/6 Buy: Both investors and traders may wish to take another look at WPL. The recent pullback and higher low at $23 provide another opportunity to buy the stock.
Traders may consider a stop loss below 23.10.
IPL:ASX is now under Algo Engine buy conditions and has been added to the ASX 100 model portfolio.
We expect to see a pick up in second half earnings for IPL, which will help support the share price.
Traders will note the high low formation at $2.35 and may wish to run a stop loss below this level.